Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adiponectin, C1Q and collagen domain containing (ADIPOQ)
- Target
- ADIPOQ
- Molecular classification
- Protein/hormone, Adipokine (signaling molecule derived from adipose tissue), Member of the C1q and TNF-related protein family, Secreted glycoprotein
01
Overview
Adiponectin, C1Q and collagen domain containing (ADIPOQ) is a secreted protein produced exclusively by adipose tissue. It circulates in plasma and structurally resembles collagens and complement factor C1q. Adiponectin is a multifunctional adipokine regulating glucose and lipid metabolism, improving insulin sensitivity, and exerting anti-inflammatory, anti-diabetic, and anti-atherogenic effects. It activates AMP-activated protein kinase (AMPK) pathways in muscle and liver, enhances glucose and fatty acid usage, and antagonizes inflammatory cytokines such as TNF-alpha. Clinical interest in adiponectin centers on its role in metabolic diseases, cardiovascular disease, and as a biomarker for insulin resistance and risk assessment.
- Other names
- AdiponectinACRP30GBP28ApM1ACDCAdipose Most Abundant Gene Transcript 1 Protein30 kDa Adipocyte Complement-Related ProteinAdipocyte Complement-Related 30 kDa ProteinAdipocyte, C1q and collagen domain-containing protein
02
Mechanism of action
Drugs increasing adiponectin levels act via enhanced gene expression and secretion in adipocytes. Drugs may act through agonism of the PPARγ receptor, resulting in upregulated adiponectin synthesis and secretion.
03
Biological functions
Control of fat metabolismRegulation of insulin sensitivityAnti-diabetic activitiesAnti-atherogenic activitiesAnti-inflammatory activitiesAMPK pathway activationRegulation of glucose and fatty-acid utilizationAntagonism of TNF-alpha effectsInhibition of NF-kappaB signalingModulation of angiogenesis and tissue remodeling
04
Disease associations
Type 2 diabetes mellitus (insulin resistance)Prediabetes syndromeCardiovascular disease (atherosclerosis)Obesity/metabolic syndromeInflammation
05
Safety considerations
No major safety concerns directly attributed to adiponectin targeting; however, drugs that raise adiponectin (such as PPARγ agonists) carry risk of fluid retention, weight gain, and possible cardiovascular effects
06
Interacting drugs
Investigational agents aiming to raise adiponectin levels (e.g., thiazolidinediones, nutritional compounds)
1 more in the full profile.
07
Biomarkers
Plasma adiponectin levels are used as biomarkers for metabolic syndrome, insulin resistance, and cardiovascular risk
Beyond the preview
Go deeper on Adiponectin, C1Q and collagen domain containing (ADIPOQ).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adiponectin, C1Q and collagen domain containing (ADIPOQ).